Results 171 to 180 of about 186,436 (335)

Inflammatory Cytokines as Early Predictors of Weaning Failure From Extracorporeal Life Support

open access: yesArtificial Organs, EarlyView.
Levels of IL‐8 and IL‐6 and their dynamics are reliable early predictors of ECLS weaning failure. ABSTRACT Background Weaning from extracorporeal life support (ECLS) in patients with refractory shock still remains a complex decision. Despite considerable advances in ECLS management, reliable biomarkers to predict weaning success are still not available.
Kostiantyn Kozakov   +11 more
wiley   +1 more source

In-silico Inducibility of Ventricular Tachycardia in Patient-Specific Post-Infarction Ventricular Models

open access: bronze, 2022
Javier Villar Valero   +5 more
openalex   +1 more source

Percutaneous Versus Surgical Cannulation for Femoro‐Femoral Venoarterial Extracorporeal Membrane Oxygenation: A Retrospective Cohort Study on Cannulation‐Related Complications

open access: yesArtificial Organs, EarlyView.
Percutaneous femoro‐femoral V‐A ECMO cannulation was associated with more than a two‐fold lower risk of site bleeding and nearly a six‐fold lower risk of infection compared with surgical cut‐down, with no difference in limb ischemia. Absence of distal perfusion catheterization and larger arterial cannula size were additional modifiable ischemia risk ...
Axel Dimberg   +3 more
wiley   +1 more source

Overlooked and Underdiagnosed: Cardiac Sarcoidosis and Unexplained Ventricular Tachycardia and Fibrillation. [PDF]

open access: yesJACC Adv
Sifuentes AA   +6 more
europepmc   +1 more source

136-33: Utility of pace-matching using the PaSo module for catheter ablation of Idiopathic ventricular tachycardia [PDF]

open access: bronze, 2016
Gustavo Lima da Silva   +11 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Catecholaminergic polymorphic ventricular tachycardia in children-incidence and trends in detection, presentation and management. [PDF]

open access: yesArch Dis Child
Fitzgerald N   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy